Compare WTO & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WTO | SILO |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Apparel |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 4.5M |
| IPO Year | 2021 | N/A |
| Metric | WTO | SILO |
|---|---|---|
| Price | $0.78 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 733.9K | 186.2K |
| Earning Date | 01-20-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $34,589,265.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 54.01 | N/A |
| 52 Week Low | $0.55 | $0.33 |
| 52 Week High | $440.00 | $3.37 |
| Indicator | WTO | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 49.11 | 45.01 |
| Support Level | $0.78 | $0.33 |
| Resistance Level | $0.91 | $0.43 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 37.80 | 48.57 |
UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.